FDA Clearance Tracker · P110041
ADVIA CENTAUR HBSAGII
Last checked: Nov 20, 2026Latest source record: May 16, 2014 (this decision)Source: openFDAMethods & limitations
Decided
May 16, 2014
Approved (reclassified)
Time to decision
879 days
Received Dec 19, 2011. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class II
The decision
- FDA number
- P110041
- Device name
- ADVIA CENTAUR HBSAGII
- Applicant
- Siemens Corp.
- Applicant location
- Tarrytown, NY
- Received
- Dec 19, 2011
- Decided
- May 16, 2014
- Decision
- Approved (reclassified)
- Supplements
- 17 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.3172
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE ADVIA CENTAUR HBSAGII, ADVIA CENTAUR HBSAG CONFIRMATORY, AND ADVIA CENTAUR HBSAG QUALITYCONTROL MATERIAL. THIS DEVICE IS INDICATED FOR:ADVIA CENTAUR HBSAGII (HBSII) -THE ADVIA CENTAUR HBSAGII (HBSII) ASSAY IS AN IN VITRO IMMUNOASSAY FOR THE QUALITATIVEDETECTION OF HEPATITIS B SURFACE ANTIGEN (HBSAG) IN HUMAN ADULT, ADOLESCENT, AND PEDIATRIC SERUM AND PLASMA (EDT A, LITHIUM-HEPARIN, OR SODIUM-HEPARIN), AND NEONATAL SAMPLES USINGTHE ADVIA CENTAUR AND ADVIA CENTAUR XP SYSTEMS. THE ASSAY MAY BE USED IN CONJUNCTIONWITH OTHER SEROLOGICAL AND CLINICAL INFORMATION TO DIAGNOSE INDIVIDUALS WITH ACUTE OR CHRONICHEPATITIS B INFECTION. THE ASSAY MAY ALSO BE USED TO SCREEN FOR HEPATITIS B INFECTION IN PREGNANT WOMEN TO IDENTIFY NEONATES WHO ARE AT RISK OF ACQUIRING HEPATITIS B DURING THE PERINATAL PERIOD.ADVIA CENTAUR HBSAG CONFIRMATORYTHE ADVIA CENTAUR HBSAG CONFIRMATORY ASSAY IS AN IN VITRO IMMUNOASSAY FOR THE CONFIRMATION OF HEPATITIS B SURFACE ANTIGEN (HBSAG) IN HUMAN SERUM AND PLASMA (POTASSIUMEDTA, LITHIUM-HEPARIN, OR SODIUM-HEPARIN), AND NEONATAL SAMPLES USING THE ADVIA CENTAUR AND ADVIA CENTAUR XP SYSTEMS. THE ASSAY IS INTENDED TO BE USED TO CONFIRM THE PRESENCE OFHBSAG IN SAMPLES THAT ARE REPEATEDLY REACTIVE USING THE ADVIA CENTAUR HBSAGII ASSAY.ADVIA CENTAUR HBSAG QUALITY CONTROL MATERIALFOR MONITORING THE PERFORMANCE OF THE HBSAG, HBSAGII AND HBSAG CONFIRMATORY ASSAYS ON THE ADVIA CENTAUR SYSTEMS. THE PERFORMANCE OF THE HBSAG QUALITY CONTROL MATERIAL HAS NOT BEEN ESTABLISHED WITH ANY OTHER HBSAG OR HBSAG CONFIRMATORY ASSAYS.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code LOM. The earliest in FDA's data is P780016-S002, decided Mar 17, 1980.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Siemens Corp.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.